— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —
— FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for...